Cleo Enhances Board Capacity

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) confirms current Chief Scientific Officer and Executive Director, Dr Andrew Stephens, role will move to full-time effective 1 October, 2023.

---

Following the Company’s successful listing on the ASX in August, Dr Andrew Stephens has agreed to expand his commitment to the Company by moving his Chief Scientific Officer and Executive Director responsibilities to full-time, up from three days per week part-time. All remaining terms and conditions of Dr Stephens employment agreement are unchanged.

The enhancement to Cleo’s Board capacity is designed to direct clear executive focus on the Company’s phased development strategy to deliver a simple and accurate blood test capable of detecting ovarian cancer at every stage.

Commenting on the enhanced Board capacity, CLEO Chief Executive, Richard Allman, said:

“It is pleasing to see Dr Stephens expand his time commitment to Cleo which will effectively allow the Company to step up our ability to execute on our development program and strategy. It also further reinforces the confidence and conviction Cleo has in bringing our cancer diagnostics technology to market as soon as possible.”

Dr Andrew Stephens, added:

“The urgency to address the global unmet meet for accurate and early diagnosis of ovarian cancer is clear. I look forward to dedicating my focus full-time alongside the Board, my colleagues, and partners to advance Cleo’s ambition to address ovarian cancer through a simple and accurate blood test.

Click here for the full ASX Release

This article includes content from CLEO Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here .